FindTrial
Sign In

Dara SC

DRUG3 trials

Sponsors

Janssen Pharmaceutical K.K., Janssen Research & Development, LLC, Peking University People's Hospital

Conditions

Multiple MyelomaSystemic AL Amyloidosis

Phase 1

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
CompletedNCT03242889
Janssen Pharmaceutical K.K.Multiple Myeloma
Start: 2017-08-10End: 2023-02-10Updated: 2023-04-14

Phase 3

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
CompletedNCT03277105
Janssen Research & Development, LLCMultiple Myeloma
Start: 2017-10-27End: 2024-01-12Updated: 2025-04-29

Unknown Phase

Rapid dFLC Response Predict CHR in AL Amyloidosis
RecruitingNCT06627309
Peking University People's HospitalSystemic AL Amyloidosis
Start: 2024-10-26End: 2026-12-31Target: 50Updated: 2026-03-09

Related Papers

Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas
BMJ Open2025-02-014 citations
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma.
2023-04-061 citations
PB1995: SAFETY OF SUBCUTANEOUS DARATUMUMAB IN MULTIPLE MYELOMA: A RETROSPECTIVE MULTI-CENTER REAL LIFE EXPERIENCE
HemaSphere2022-06-011 citations
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
Haematologica2022-03-3143 citations
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
2021-02-186 citations
Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
Blood2020-11-05
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
2020-09-111 citations
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
Journal of Cancer Research and Clinical Oncology2020-08-2728 citations
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
2020-03-23165 citations
Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update
Blood2019-11-1316 citations
Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba
Blood2019-11-135 citations
S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA
HemaSphere2019-06-012 citations
Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Journal of Clinical Oncology2019-05-2024 citations
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Blood2018-11-291 citations
Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Journal of Clinical Oncology2018-05-206 citations